United States - English - NLM (National Library of Medicine)

sagent pharmaceuticals - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5%. desmopressin acetate injection will often maintain hemostasis in patients with hemophilia a during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. desmopressin acetate injection will also stop bleeding in hemophilia a patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. in certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor viii levels between 2% to 5%; however, these patients should be carefully monitored. desmopressin acetate injection is indicated for patients with mild to moderate classic von willebrand's disease (type i) with factor viii levels greater than 5%. desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von willebrand's disease during

United States - English - NLM (National Library of Medicine)

american regent, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate injection 4 mcg/ml is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5%. desmopressin acetate will often maintain hemostasis in patients with hemophilia a during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. desmopressin acetate will also stop bleeding in hemophilia a patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. desmopressin acetate is not indicated for the treatment of hemophilia a with factor viii coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia b, or in patients who have factor viii antibodies. in certain clinical situations, it may be justified to try desmopressin acetate in patients with factor viii levels between 2% to 5%; however, these patients should be carefully monitored. desmopressin acetate injection 4 mcg/ml is indicated for patients with mild to mo

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. desmopressin acetate tablets are contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate tablets. desmopressin a

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. desmopressin acetate tablets are contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate tablets. desmopressin a

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. desmopressin acetate tablets are contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate tablets. desmopressin acetate tablets are contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50 ml/min). desmopressin acetate tablets are contraindicated in patients with hyponatremia or a history of hyponatremia.

United States - English - NLM (National Library of Medicine)

dr. reddy's laboratories inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate injection is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. limitations of use: desmopressin acetate injection is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. desmopressin acetate injection is indicated for patients with hemophilia a with factor viii coagulant activity levels greater than 5% without factor viii antibodies to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. desmopressin acetate injection is indicated for patients with mild to moderate von willebrand’s disease (type i) with factor viii levels greater than 5% to: - maintain hemostasis during surgical procedures and postoperatively - reduce bleeding with epi

United States - English - NLM (National Library of Medicine)

american health packaging - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. desmopressin acetate tablets are contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate tablets. desmopressin acetate tablets are contraindicated in patients with moderate to severe renal impairment (defined as a creatinine clearance below 50ml/min). desmopressin acetate is contraindicated in patients with hyponatremia or a history of hyponatremia.

United States - English - NLM (National Library of Medicine)

bluepoint laboratories - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. desmopressin acetate tablets are contraindicated in individuals with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate tablets. desmopressin a

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate nasal solution (nasal spray) is indicated as antidiuretic replacement therapy in the management of central diabetes insipidus in adults and pediatric patients 4 years of age and older. limitations of use: desmopressin acetate nasal solution (nasal spray) is not indicated for: - treatment of nephrogenic diabetes insipidus, - treatment of primary nocturnal enuresis [see warnings and precautions (5.1) ], - use in patients with conditions that compromise the intranasal route of administration (e.g., severe nasal congestion and blockage, nasal mucosa atrophy, severe atrophic rhinitis, recent nasal surgery such as transsphenoidal hypophysectomy) [see warnings and precautions (5.2)]. - use in patients with an impaired level of consciousness, - use in patients requiring doses less than 10 mcg or doses that are not multiples of 10 mcg [see dosage forms and strengths (3)]. desmopressin acetate nasal solution (nasal spray) is contraindicated in patients with: -   known hypersensitivity to desmopres

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - desmopressin acetate (unii: xb13hyu18u) (desmopressin - unii:enr1llb0fp) - desmopressin acetate nasal solution 0.01% (nasal spray) is indicated as antidiuretic replacement therapy in the management of central diabetes insipidus in adults and pediatric patients 4 years of age and older. limitations of use: desmopressin acetate nasal solution 0.01% (nasal spray) is not indicated for: • treatment of nephrogenic diabetes insipidus, • treatment of primary nocturnal enuresis [see warnings and precautions (5.1)], • use in patients with conditions that compromise the intranasal route of administration (e.g., severe nasal congestion and blockage, nasal mucosa atrophy, severe atrophic rhinitis, recent nasal surgery such as transsphenoidal hypophysectomy) [see warnings and precautions (5.2)]. • use in patients with an impaired level of consciousness, • use in patients requiring doses less than 10 mcg or doses that are not multiples of 10 mcg [see dosage forms and strengths (3)]. desmopressin acetate nasal solution 0.01% (nasal spray) is contraindicated in patients with: • known hypersens